Evidence map›Paper›PMID 29464496›Full record

ArticleMolecular imaging and biology2018

Tumor Targeting via Sialic Acid: [

Charalambos Tsoukalas, Simonetta Geninatti-Crich, Anastasios Gaitanis, Theodoros Tsotakos, Maria Paravatou-Petsotas, Silvio Aime, Rogelio Jiménez-Juárez, Constantinos D Anagnostopoulos, Kristina Djanashvili, Penelope Bouziotis

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. MRI Contrast Agents in Glycobiology.Molecules (Basel, Switzerland) · 2022
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Charalambos TsoukalasInstitute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", Aghia Paraskevi, 153 10, Athens, Greece.
Simonetta Geninatti-CrichDepartment of Molecular Biotechnology and Health Sciences, University of Turin, via Nizza 52, Torino, Italy.
Anastasios GaitanisBiomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou Street, 115 27, Athens, Greece.
Theodoros TsotakosInstitute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", Aghia Paraskevi, 153 10, Athens, Greece.
Maria Paravatou-PetsotasInstitute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", Aghia Paraskevi, 153 10, Athens, Greece.
Silvio AimeDepartment of Molecular Biotechnology and Health Sciences, University of Turin, via Nizza 52, Torino, Italy.
Rogelio Jiménez-JuárezDepartment of Organic Chemistry, National School of Biological Sciences, National Polytechnical Institute, Prolongación de Carpio y Plan de Ayala S/N, 11340, Mexico D.F., Mexico.
Constantinos D AnagnostopoulosBiomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou Street, 115 27, Athens, Greece.
Kristina DjanashviliDepartment of Biotechnology, Delft University of Technology, Van der Maasweg, 2629 HZ, Delft, Netherlands.
Penelope BouziotisInstitute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", Aghia Paraskevi, 153 10, Athens, Greece. bouzioti@rrp.demokritos.gr.ORCID http://orcid.org/0000-0001-6778-2201
National Centre of Scientific Research "Demokritos" · GRAcademy of Athens · GRDelft University of Technology · NLUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to demonstrate the potential of Ga-68-labeled macrocycle (DOTA-en-pba) conjugated with phenylboronic vector for tumor recognition by positron emission tomography (PET), based on targeting of the overexpressed sialic acid (Sia). PROCEDURES: The imaging reporter DOTA-en-pba was synthesized and labeled with Ga-68 at high efficiency. Cell binding assay on Mel-C and B16-F10 melanoma cells was used to evaluate melanin production and Sia overexpression to determine the best model for demonstrating the capability of [

resultsThe affinity of [

conclusionsOur work is the first attempt for in vivo imaging of cancer by targeting overexpression of sialic acid on cancer cells with a radiotracer in PET.

Indexed as

Molecular ImagingPositron-Emission TomographyAnimalsCell Line, TumorFemaleGallium RadioisotopesMelanoma, ExperimentalMetabolomeMice, SCIDN-Acetylneuraminic AcidNeoplasmsRadiopharmaceuticalsTissue DistributionGallium-68Gallium RadioisotopesN-Acetylneuraminic AcidRadiopharmaceuticalsGallium-68PET imagingPhenylboronic targeting vectorSialic acidTumor recognition

Identifiers

PMID29464496
OpenAlexW2790569765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.